Janet Lambert
Janet Lambert is the CEO of the Alliance for Regenerative Medicine (ARM). ARM is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory and reimbursement initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 11-year history, ARM has become the voice of the sector, representing the interests of 350+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
ARTICLES BY JANET LAMBERT
-
![Janet Lambert, CEO of ARM]( "Why We Need A New Model To Appropriately Value The Promise Of Regenerative Medicines & Advanced Therapies")
Why We Need A New Model To Appropriately Value The Promise Of Regenerative Medicines & Advanced Therapies7/27/2020With durable or curative therapies near at hand for a range of severe diseases and disorders, it has become clear that payors need a different model for assessing the value of these innovative treatments.
-
![Janet Lambert, CEO, and Michael Lehmicke, Director, Science and Industry Affairs, ARM]( "Creating A Roadmap For The Development And Manufacture Of Gene Therapies")
Creating A Roadmap For The Development And Manufacture Of Gene Therapies5/4/2020The cell and gene therapy sector is in need of a similar revolution, but instead of a “standard gauge,” there is a need for clear, evidence-based industry standards and best practices for manufacturing these innovative technologies.
-
![Speaker-Podium-Microphone]( "State Of The Cell And Gene Therapy Sector — Clinical, Financial, And Regulatory Perspectives")
State Of The Cell And Gene Therapy Sector — Clinical, Financial, And Regulatory Perspectives10/4/2018The regenerative medicine sector is at a remarkable moment. Transformative products are now on the market and accessible to greater numbers of patients every day. Dozens of additional therapies are in late stage studies. The regulatory and policy environment has evolved rapidly alongside the science, enabling a surge of incoming innovation.
